Evidence map›Paper›PMID 40640524›Full record

ArticleCancer gene therapy2025

DR1 activates histone gene expression to maintain pancreatic cancer cell survival through the ATAC complex.

Ziwei Guo, XiangZheng Liu, Mo Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ziwei GuoState Key Laboratory of Molecular Oncology, School of Basic Medical Sciences, Tsinghua University, Beijing, 100084, China.
XiangZheng LiuState Key Laboratory of Molecular Oncology, School of Basic Medical Sciences, Tsinghua University, Beijing, 100084, China.
Mo ChenState Key Laboratory of Molecular Oncology, School of Basic Medical Sciences, Tsinghua University, Beijing, 100084, China. mochen@mail.tsinghua.edu.cn.ORCID http://orcid.org/0000-0002-6647-8483

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32370589Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation) JQ23024
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most malignant cancer and is characterized by short survival and limited treatment options. Epigenetic dysregulation is a defining feature of tumorigenesis but remains elusive in PDAC. Here, we identified DR1 as a vulnerability in PDAC. Loss of DR1 inhibited PDAC cell survival through repressing cell cycle. Mechanistically, DR1 recruited the ATAC complex to histone promoter regions to acetylate H3K9 and subsequently activate the expression of histone genes, ultimately promoting cell cycle and maintaining PDAC cell survival. Moreover, we uncovered a positive correlation between histone gene expression and the survival of patients with PDAC. In conclusion, our findings underscore the pivotal role of DR1 in the regulation of histone genes through the ATAC complex, providing a potential therapeutic target for PDAC.

Indexed as

Carcinoma, Pancreatic DuctalGene Expression Regulation, NeoplasticHistonesPancreatic NeoplasmsAnimalsCell Line, TumorCell SurvivalHumansMiceHistones

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.